Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
Abstract
Share and Cite
Pokorska-Śpiewak, M.; Dobrzeniecka, A.; Aniszewska, M.; Marczyńska, M. Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project. J. Clin. Med. 2021, 10, 4176. https://doi.org/10.3390/jcm10184176
Pokorska-Śpiewak M, Dobrzeniecka A, Aniszewska M, Marczyńska M. Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project. Journal of Clinical Medicine. 2021; 10(18):4176. https://doi.org/10.3390/jcm10184176
Chicago/Turabian StylePokorska-Śpiewak, Maria, Anna Dobrzeniecka, Małgorzata Aniszewska, and Magdalena Marczyńska. 2021. "Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project" Journal of Clinical Medicine 10, no. 18: 4176. https://doi.org/10.3390/jcm10184176
APA StylePokorska-Śpiewak, M., Dobrzeniecka, A., Aniszewska, M., & Marczyńska, M. (2021). Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project. Journal of Clinical Medicine, 10(18), 4176. https://doi.org/10.3390/jcm10184176